Filtered By:
Specialty: Drugs & Pharmacology
Condition: Thrombosis

This page shows you your search results in order of relevance. This is page number 19.

Order by Relevance | Date

Total 546 results found since Jan 2013.

Evaluation of Prescribing Practices and Outcomes Using Direct-Acting Oral Anticoagulants After Cardiac Surgery
Clin Ther. 2021 May 30:S0149-2918(21)00203-4. doi: 10.1016/j.clinthera.2021.04.009. Online ahead of print.ABSTRACTPURPOSE: Cardiac surgery patients frequently require anticoagulation. Warfarin remains the preferred agent, and a few trials have reported negative outcomes with the use of direct-acting oral anticoagulants (DOACs) in these patients. Therefore, limited literature exists that supports the dosing, safety, and efficacy of DOACs within the cardiac surgery population.METHODS: This single-center, retrospective analysis was conducted at a tertiary academic medical center. All data were extrapolated from electronic med...
Source: Clinical Therapeutics - June 3, 2021 Category: Drugs & Pharmacology Authors: Dareen M Kanaan Bryan M Cook Julie Kelly Rhynn Malloy Source Type: research

The Protective Effect of Liquiritin in Hypoxia/Reoxygenation-Induced Disruption on Blood Brain Barrier
Conclusions: Studies have shown that LQ can promote cell proliferation, migration as well as angiogenesis, and reduce cell apoptosis, which may be related to its inhibition of oxidative and ER stress, and then maintain the integrity of BBB. Given that five differential proteins were found by protein analysis, future studies will revolve around the five differential proteins.
Source: Frontiers in Pharmacology - July 6, 2021 Category: Drugs & Pharmacology Source Type: research

Efficacy and Safety of Direct Oral Anticoagulants Versus Vitamin K Antagonists in the Treatment of Left Ventricular Thrombus: A Systematic Review and Meta-analysis
Conclusions: DOACs seem to be more efficacious in achieving LVT resolution compared with VKAs. However, there was no significant difference between the 2 groups in thromboembolic events, major bleeding, and all-cause mortality. Randomized controlled trials are needed to confirm our findings.
Source: American Journal of Therapeutics - July 1, 2021 Category: Drugs & Pharmacology Tags: Meta-analysis Source Type: research

Bivalirudin versus unfractionated heparin during percutaneous coronary intervention in high-bleeding-risk patients with acute coronary syndrome in contemporary practice
CONCLUSIONS: The treatment of bivalirudin showed better efficacy and safety as compared to UFH among patients with ACS undergoing PCI at high risk of bleeding in contemporary practice.PMID:34321166 | DOI:10.1016/j.biopha.2020.110758
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - July 29, 2021 Category: Drugs & Pharmacology Authors: Yahao Zhang Yanghui Zhang Zhiyu Liu Bin Zhang Guizhi Liu Kui Chen Source Type: research

A Review of Direct Oral Anticoagulants in Patients With Stage 5 or End-Stage Kidney Disease
CONCLUSIONS: If OACs for stroke prevention with AF are deemed necessary, apixaban or rivaroxaban can be considered. DOACs cannot currently be recommended over warfarin in patients with CKD-5 or ESKD and VTE.PMID:34459281 | DOI:10.1177/10600280211040093
Source: The Annals of Pharmacotherapy - August 30, 2021 Category: Drugs & Pharmacology Authors: Jessica A Starr Nathan A Pinner Melanie Mannis Mary Katherine Stuart Source Type: research

Effect of Apixaban Pretreatment on Alteplase-Induced Thrombolysis: An In Vitro Study
Benefit of thrombolytic therapy in patients with acute stroke, who are on anticoagulant treatment, is not well addressed. The aim of this study was to investigate whether apixaban can modify the thrombolytic efficacy of alteplase in vitro. Static and flow models and two variants of red blood cell (RBC) dominant clots, with and without apixaban, were used. Clots were prepared from the blood of healthy human donors and subsequently exposed to alteplase treatment. Apixaban and alteplase were used in clinically relevant concentrations. Clot lysis in the static model was determined both by clot weight and spectrophotometric det...
Source: Frontiers in Pharmacology - September 15, 2021 Category: Drugs & Pharmacology Source Type: research

COVID-19 and the Cardiovascular System: Insights into Effects and Treatments
Can J Physiol Pharmacol. 2021 Sep 21. doi: 10.1139/cjpp-2021-0093. Online ahead of print.ABSTRACTCoronavirus disease 2019 (COVID-19), an acute and highly transmissible infectious disease has reached a pandemic level since March 11, 2020 and continues to challenge the healthcare system worldwide. The pathogenesis of COVID-19 is a complex process involving mechanisms that suppress the host antiviral and innate immune response, while triggering marked activation of coagulation and hyperinflammation leading to cytokine storm in severe COVID-19. This review summarizes current evidence related to COVID-19-associated cardiovascul...
Source: Canadian Journal of Physiology and Pharmacology - September 21, 2021 Category: Drugs & Pharmacology Authors: Joey-Bahige Chammas Dylan Delaney Naim Chabaytah Sarah Abdulkarim Adel Schwertani Source Type: research

Apixaban and rivaroxaban use for atrial fibrillation in patients with obesity and BMI ≥50 kg/m2
ConclusionsThis study demonstrated that apixaban and rivaroxaban in patients with a BMI ≥50 kg/m2 for treatment of NVAF may be safe and effective at preventing thromboembolic events and had no increased risk of bleeding. Although, findings should be interpreted with caution and confirmed with additional studies. This study contributes to the growing body of evidence that direct oral anticoagulants (DOACs) may be effective and safe to use for the treatment of NVAF in patients with BMI ≥50 kg/m2.
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - November 25, 2021 Category: Drugs & Pharmacology Authors: Cavan P. O ’Kane, Juan Carlo O. Avalon, Jordan L. Lacoste, Wei Fang, Christopher M. Bianco, Laura Davisson, Kara L. Piechowski Tags: ORIGINAL RESEARCH ARTICLE Source Type: research

Clinical Pharmacokinetics and Pharmacodynamics of Desmoteplase
AbstractDesmoteplase is a bat (Desmodus rotundus) saliva-derived fibrinolytic enzyme resembling a urokinase and tissue plasminogen activator. It is highly dependent on fibrin and has some neuroprotective attributes. Intravenous administration of desmoteplase is safe and well tolerated in healthy subjects. Plasma fibrinolytic activity is linearly related to its blood concentration, its terminal elimination half-life ranges from 3.8 to 4.92  h (50 vs. 90 μg/kg dose). Administration of desmoteplase leads to transitory derangement of fibrinogen, D-dimer, alpha2-antiplasmin, and plasmin and antiplasmin complex which normaliz...
Source: European Journal of Drug Metabolism and Pharmacokinetics - December 11, 2021 Category: Drugs & Pharmacology Source Type: research